

HEALTH AND SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND COMPANY				
COMPANY ADDRESS: Dechra Pharmaceuticals PLC 24 Cheshire Avenue Cheshire Business Park Lostock Gralam Northwich CW9 7UA UK Tel: +44 (0) 1606 814730 Fax: +44 (0) 1606 814731	PRODUCT NAMES:	ISSUE DATE: 29 May 2015		
	LEVOCRINE® Chewable Tablets (levothyroxine Sodium)	PHYSICAL FORM: Chewable Tablet		
		PRODUCT TYPE: Thyroid Replacement for hypothyroidism in canines		
		CONTAINER: 180 and 1,000 count light- resistant bottles		
2. HAZARDS IDENTIFICATION: May cause adverse heart and central nervous system effects. Keep out of reach of children.				
3. COMPOSITION/INFORMATION ON ACTIVE INGREDIENTS				
	<u>S Number</u> 16-65-3 1.0mg	.5, 0.6, 0.7, 0.8 or		



4. FIRST-AID MEASURES

EYE CONTACT:	Not an expected route of entry. If tablet comes into contact with the eye, immediately rinse eyes with running water and seek medical advice is pain or irritation persists.
DERMAL CONTACT:	Wash skin thoroughly with soap and water. Obtain medical attention if redness or soreness persists.
INGESTION:	Seek medical advice immediately if ingested. Physician may call a poison control center for advice concerning human ingestion. Treatment involves activated charcoal and possibly propranolol.
INHALATION:	Not applicable.
EQUIPMENT AT WORKPLACE:	Eye and skin washing facilities and general ventilation.

5. FIRE-FIGHTING MEASURES

Flammability: Not flammable

SUITABLE EXTINGUISHERS: All systems may be used.	EXPLOSIVE HAZARDS: None known.
EXTINGUISHERS NOT TO BE USED: N/A	
SPECIAL PROTECTIVE EQUIPMENT: Wear full protective clothing and self-contained breathing apparatus.	HAZARDOUS COMBUSTION PRODUCTS: N/A

6. ACCIDENTAL RELEASE MEASURES

PERSONAL PROTECTION:	Proper protective equipment should be used.
SPILLAGE CLEAN-UP:	Sweep and dispose of small amounts in trash. Large amounts should be disposed of in a sanitary landfill.



7. HANDLING AND STORAGE		
	After handling tablets and dispensing to dog, wash hands before eating, drinking or smoking.	
and	Store in original container at temperatures between 59° F and 86° F (15° C - 30° C). Keep out of sunlight. Keep out of the reach and sight of children.	
 8. EXPOSURE CONTROLS/PERSONAL PROTECTION: Good general room ventilation is expected to be adequate to control airborne levels. When using, do not eat or drink. Do not smoke. Wear suitable protective clothing. Wash hands with soap and water after handling. 		
9. PHYSICAL AND CHEMICAL PROPERTIES OF PRODUCT		
APPEARANCE:	MELTING POINT ℃:	
Brown, round, scored tablet with milligrams imprinted. Artificial meat aroma.	N/A	
	N/A BOILING POINT ℃: N/A	
imprinted. Artificial meat aroma.	BOILING POINT ℃:	



11. TOXICOLOGICAL INFORMATION		
EYE CONTACT:	No relevant studies identified.	
DERMAL CONTACT:	No relevant studies identified. Skin reactions rarely reported.	
INGESTION:	May result in gastrointestinal intolerance. Large overdose May result in adverse heart and central nervous system effects: tachycardia, arrhythmias, angina pectoris, headache, hypertension, insomnia, nervousness, hyperkinesis, tremors, diaphoresis, hot skin, hyperadrenocorticism, collapse and coma. Such symptoms may be delayed for days.	
INHALATION:	No relevant studies identified.	
12. ECOLOGICAL INFORMATION (active):	No relevant studies identified.	
13. DISPOSAL CONSIDERATIONS:	Dispose of any unused product and empty containers in accordance with guidance from your local and national waste regulation authorities	
14. TRANSPORT INFORMATION:	This product is not classified as hazardous. Transport in accordance with good industrial hygiene practices.	
 15. REGULATORY INFORMATION US Regulations (Federal, State) and International Chemical Registration Laws TSCA Listing This product contains ingredients that are listed on or exempt from listing on the EPA Toxic Substance Control Act Chemical Substance (TSCA) Inventory. DSL (Canadian) Listing This product contains ingredients that are listed on the Domestic Substance List (DSL) or Non- Domestic Substance List (NDSL). WHMIS Classification This product is not a controlled substance under WHMIS. 		

16. OTHER INFORMATION

Prepared by Dechra Pharmaceuticals PLC on the basis of the best available data. No representation is given that the information provided is complete in all respects.